LL-37 is different from many peptides discussed for performance, metabolism or recovery. It is the only human cathelicidin antimicrobial peptide and forms part of the body’s first-line defence against microorganisms.
Research interest in LL-37 comes from its broader biological role. It has been studied for antimicrobial activity, immune signalling, inflammation, wound healing and tissue repair. That combination makes it relevant to researchers looking at both microbial defence and regeneration.
This guide explains what LL-37 is, why it is discussed in relation to biofilms and wound healing, and what to consider when comparing peptides SA suppliers for research use.
What is LL-37?
LL-37 is a naturally occurring 37-amino acid cationic peptide derived from hCAP18, also known as human cathelicidin. Cathelicidins are part of innate immunity, which is the rapid defence system the body uses before the adaptive immune system has developed a targeted response.
LL-37 is produced in barrier and immune-related tissues, including the skin, respiratory tract, gastrointestinal tract and immune system. These are high-contact areas where the body regularly encounters bacteria, viruses, fungi and other environmental microorganisms.
Its best-known feature is broad-spectrum antimicrobial activity. In research settings, LL-37 is explored for activity against bacteria, viruses and fungi. It is also studied for how it influences immune responses rather than only for direct antimicrobial effects.
How LL-37 works in antimicrobial research
LL-37 is often described as an antimicrobial peptide because it can interact directly with microbial membranes. Its cationic structure allows it to associate with negatively charged microbial surfaces, and one proposed mechanism involves membrane disruption.
That direct action is only part of the picture. LL-37 is also classed as an immunomodulatory peptide, meaning it can influence immune communication. It may affect inflammatory signalling pathways, including pathways involving Toll-like receptors, which help immune cells recognise microbial patterns.
This is why LL-37 is scientifically interesting. It sits between microbial defence and immune coordination. It is studied as a peptide that may help shape the local response to microbial challenge while also participating in the repair processes that follow tissue damage.
Why LL-37 is discussed in relation to biofilms
Biofilms are structured microbial communities surrounded by a protective extracellular matrix. Bacteria and fungi can form biofilms on tissue surfaces and other environments, making them harder for immune mechanisms and antimicrobial agents to reach.
LL-37 has attracted attention because laboratory research has explored its effects on biofilm formation and microbial organisation. A 2019 PLOS ONE study by Noore and colleagues reported more than a 4 log reduction in MRSA biofilms compared with conventional antibiotics in that experimental model.
That finding should be read carefully. Biofilms vary by organism, environment and maturity. Laboratory biofilm results do not mean LL-37 is a proven answer for chronic infections or all biofilm-related conditions. The value of the work is that it helps researchers understand how antimicrobial peptides may interact with resistant microbial communities.
LL-37 and wound healing research
LL-37 is also studied for wound healing because damaged tissue creates two overlapping problems. The barrier is compromised, increasing exposure to microorganisms, and the tissue also needs to rebuild.
Research on LL-37 has explored several repair-related processes:
keratinocyte migration into damaged tissue
angiogenesis, or the formation of new blood vessels
epithelial cell proliferation
collagen-related tissue repair activity
inflammatory regulation during healing
The strongest clinical reference in the supplied data relates to chronic venous leg ulcers. A 2014 study by Grönberg and colleagues in Wound Repair and Regeneration reported a 68% ulcer area reduction at a 0.5 mg/mL concentration in chronic venous leg ulcers.
LL-37 is also discussed in research involving diabetic foot ulcers, pressure ulcers and skin repair models. These areas remain research-focused and should not be presented as established treatment claims. PeptideSupermarket®’s peptide price comparison page
Research areas for LL-37
The following table summarises the main areas where LL-37 is discussed in the supplied peptide profile. It is a research overview, not a treatment guide.
Research areaWhy LL-37 is studiedEvidence framingChronic venous leg ulcersWound area reduction and local repair signallingClinical trial data reported 68% ulcer area reduction at 0.5 mg/mLDiabetic foot ulcersGranulation tissue formation and wound closure mechanismsExplored as an effective research area in the supplied profilePressure ulcersAcceleration of healing in injury modelsAnimal model evidence is notedMRSA and resistant bacteriaAntimicrobial and biofilm-related activityLaboratory data includes strong MRSA biofilm findingsSkin health and tissue repairKeratinocyte migration, angiogenesis and collagen-related repairModerate research interest in repair mechanisms
Topical and injectable LL-37 in research contexts
Topical LL-37 is the most established route in the supplied reference data. It allows direct access to the wound site and is associated with minimal systemic exposure in research settings. This is why much of the wound-healing discussion focuses on topical gels or creams.
Injectable LL-37 is also listed in research supply contexts, usually discussed for systemic distribution and immune modulation. The available clinical data is more limited compared with topical research, so injectable use should be approached with particular caution in interpretation.
LL-37 has a short half-life because it is rapidly degraded by proteolytic enzymes. That feature matters in research design because peptide stability, formulation and route can all affect how results are interpreted.
LL-37 should not be treated as a stronger natural antibiotic. Its biology includes antimicrobial activity, immune signalling and tissue repair, and the therapeutic use of synthetic LL-37 remains experimental.
Safety considerations for LL-37 research
The supplied profile describes LL-37 as generally well tolerated in relevant research contexts, with possible local irritation at topical application sites and mild injection site reactions in injectable contexts.
More serious warning signs include severe local reactions with spreading inflammation, signs of allergic reaction such as rash, swelling or breathing difficulty, persistent flu-like symptoms, worsening wound condition, unusual pain, or signs of wound infection such as increasing redness, warmth or drainage.
Monitoring in research settings should focus on local irritation, allergic reactions, contact dermatitis, wound condition and signs of infection. The profile also flags pre-existing hypersensitivity to peptides, compromised immune status and non-sterile wound environments as important cautions.
These points are especially relevant for anyone comparing a peptide supplier SA source. Price should never be the only consideration. Product identity, concentration, labelling, analytical documentation and supplier transparency are more useful indicators when assessing research materials.
LL-37 in South Africa: what to compare before buying for research
LL-37 is increasingly listed alongside other research peptides in South Africa. Readers searching for where to buy peptides should look beyond the cheapest listing and consider whether the supplier provides clear product information.
Useful comparison points include:
whether the product is clearly labelled as LL-37
stated purity or analytical documentation where available
clear concentration, vial size and storage information
transparent pricing and shipping terms
supplier reputation and consistency of product listings
Searches such as buy peptides SA and cheap peptides can produce a wide range of results, but low price alone does not establish quality. For research materials, documentation and supplier transparency matter. Compare LL-37 prices
Frequently asked questions
What is LL-37 peptide used for in research?
LL-37 is studied for antimicrobial activity, immune modulation, biofilm-related effects and wound repair mechanisms. It is especially discussed in relation to innate immunity and topical wound-healing research.
Is LL-37 a human peptide?
Yes. LL-37 is the only human cathelicidin antimicrobial peptide. It is derived from hCAP18 and is produced in barrier and immune-related tissues such as the skin, respiratory tract and gastrointestinal tract.
Does LL-37 break down biofilms?
LL-37 has been studied for effects on biofilm formation and microbial organisation, including MRSA biofilm models. This should not be interpreted as proof that it eradicates all biofilms or resolves chronic infections.
Is topical LL-37 better studied than injectable LL-37?
According to the supplied peptide profile, topical LL-37 is the most established route and has the strongest clinical context for wound-site research. Injectable LL-37 has more limited clinical data.
Where can I compare LL-37 prices in South Africa?
You can compare LL-37 and other research peptide listings on Peptide Supermarket South Africa.
Research disclaimer
This content is for research and educational purposes only. It is not medical advice and should not be used to diagnose, treat, cure or prevent any disease.
Final thoughts on LL-37
LL-37 is best understood as a defence-and-repair peptide. It is part of human innate immunity, has broad-spectrum antimicrobial activity and is being studied for immune signalling, biofilms, wound healing and tissue regeneration.
The strongest way to read the evidence is with precision. LL-37 is well studied as a biological peptide, and several research areas are promising, but therapeutic use remains experimental.
For South African researchers comparing LL-37, assess supplier transparency, product documentation and value together. To review current listings, visit the PeptideSupermarket®’s peptide price comparison page and compare available options in one place.
Compare LL-37 prices across the UK
Side-by-side prices from every trusted UK supplier stocking LL-37.
